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ABSTRACT

Effect of Prebiotic, Probiotic, and Enzyme Supplementation on Gut Fermentation, Markers of
Inflammation and Immune Response in Individuals with GI Symptoms

by
Kaitlyn M. Webb

Current practices support the use of probiotic and prebiotic supplementation to improve chronic
gastrointestinal distress (GID). The aim of this study was to determine the tolerance and benefits
of GlutenShield (GS), a prebiotic, probiotic, and enzyme supplement, on adults with GID.
Subjects (n=20) took either GS or the placebo for 30 days and completed a pre-treatment FFQ as
well as a pre- and post-treatment GID questionnaire, blood draw, and stool sample. Participants
consumed more total and saturated fat, and less fiber and whole grains compared to the
recommended intake. A significant reduction in IgG2 was observed in the GS group (p=0.008) as
well as a significant reduction in self-reported bloating (p=0.038) with no change observed to
cytokines or SCFAs (p>0.05). GS was well tolerated and perceived to be beneficial; however,
further research is needed to identify the specific population of GID patients who could most
benefit from GS supplementation.
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CHAPTER 1
INTRODUCTION
Probiotics and prebiotics are common nutrition supplements consumed by individuals to
enhance immune function, attenuate gastrointestinal upset, improve mood and provide a host of
other benefits. Currently, probiotic and prebiotic supplements are recommended by physicians,
dietitians, and other healthcare providers to mitigate symptoms/side effects associated with
certain disease states and medications and are also supplemented to improve quality of life. The
purpose of this research is to identify if there is a relationship between GlutenShield, a
combination prebiotic, probiotic, and enzyme supplement, and the gut environment of
individuals with gastrointestinal upset. The secondary purpose is to understand the effects that
probiotics, prebiotics, and enzymes in relation to the claims currently being supported. In an
article published by the Academy of Nutrition and Dietetics on eatright.org, Registered Dietitian
Taylor Wolfram claims that probiotics “are linked to promoting the growth of helpful bacteria in
the gut,” “may boost immunity and overall health, especially GI health,” and “bottom line: At a
minimum, prebiotics and probiotics are keys for good gut health, which affects many other areas
of the body.”1 Through this research we provide complete picture of the diet, lifestyle,
fermentation, and inflammatory profile of a group of individuals with gastrointestinal upset.
From there we investigate the impact that targeted probiotic, prebiotic, and enzyme
supplementation has on gastrointestinal symptoms, mood states, fermentation, and markers of
immunity and inflammation. Research Objectives are detailed below:
1.

To determine if there is a correlation between typical dietary intake and initial fecal short
chain fatty acid concentration, markers of inflammation, and predominant gut microbial
population.
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2. To determine if pre-/probiotic/enzyme supplementation affects short chain fatty acid
production in the gut as evidenced by short chain fatty acid concentration in fecal matter
to improve digestion, absorption, and bowel function.
3. To determine whether pre-/probiotic/enzyme supplementation will improve serum
markers of inflammation, including GM-CSF, IFN-gamma, IL-2, IL-4, IL-6, IL-8, IL-10
and TNF-alpha and IgA and IgG.
4. To determine whether pre-/probiotic/enzyme supplementation will create an
improvement in psychosocial measures of self (Profile of Mood States 2nd Edition
survey).
5. To determine whether pre-/probiotic/enzyme supplementation alters the predominant gut
microbial population in feces.
6. To determine whether pre-/probiotic/enzyme supplementation alters the concentration of
microbes in feces.
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CHAPTER 2
REVIEW OF LITERATURE
Gastrointestinal Upset
Epidemiology
Symptoms of gastrointestinal (GI) upset include abdominal pain, heartburn, acid
regurgitation, bloating, nausea and vomiting, abdominal distension, eructation, increased gas,
decreased passage of stools, increased passage of stools, loose stools, hard stools, urgent need for
defecation, and feeling of incomplete evacuation.2 Chronic GI symptoms unexplained by
structural or biochemical abnormalities are common in the primary care setting; however,
epidemiological data concerning general GI symptoms is generally unavailable for the United
States/ North America.3 In the general global population, the occurrence of chronic GI symptoms
is estimated to be 5.3-20.4%.3 Further, according to Peery et al, abdominal pain resulted in
8,863,568 outpatient visits in 2009, while constipation resulted in 3,980,438 visits and diarrhea
resulted in 2,402,350 visits in the United States.4 In an effort to characterize the prevalence and
defining characteristics of GI upset, epidemiological data on constipation and diarrhea is
discussed below.
According to a systematic review conducted by Higgins et al, the prevalence of
constipation ranges from 1.9% to 27.2% in North America with an average percentage of 14.8.
Studies that relied on self-reported constipation documented a prevalence of 27.2 per 100
individuals; whereas, studies that evaluated constipation using the Rome Criteria estimated a
lower prevalence of 14.9-16.7 per 100 individuals.5 Despite the differences in criteria to evaluate
and define constipation, studies consistently reported a higher ratio of constipation in females
compared to males at 2.2:1.5 Higgins et al’s systematic review indicated that incidences of
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constipation gradually increased after age 50 and dramatically increased after age 70. 5 Very few
studies evaluate the effects of constipation on perceived quality of life and psychosocial
measures. In a survey evaluating health-related quality of life, researchers discovered a
significant difference in health related quality of life in individuals with constipation compared
to those without constipation.6 Additionally, women reported a greater impaired quality of life
compared to men.6
Based on the 2009-2010 National Health and Nutrition Examination Survey (NHANES)
bowel health questionnaire, the prevalence of chronic diarrhea in adults in the United States,
excluding inflammatory bowel disease and celiac disease, is 6.6%.7 Similar to constipation, the
incidence of chronic diarrhea is 1.4 times greater in females compared to males (p=0.004). 7 Also,
individuals with a BMI 30 and individuals over the age of 70 had a higher prevalence of
diarrhea compared to individuals with a BMI 29 and individuals between the ages of 20-29
(p0.005).7 Buono et al, using the 2012 National Health and Wellness Survey, found that
individuals with chronic diarrhea (irritable bowel syndrome- diarrhea) have a significantly lower
quality of life score (p<0.001), have higher rates of absenteeism from work (p<0.001), have
lower work productivity (p<0.001), and have higher rates of physical activity impairment
(p<0.001).8
Diet
Research on dietary intake and distribution of calories among individuals with GI
symptoms is limited. One such study compared the dietary intake of 99 individuals with
functional gastrointestinal disorders (FGIDs) to 119 individuals without symptoms (controls). 9
Using the Bowel Disease Questionnaire to evaluate GI symptoms and the Harvard Food
Frequency Questionnaire to evaluate usual dietary intake over a given week, Saito et al found
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that consumption of wheat-containing foods, lactose-containing foods, caffeinated drinks,
fructose-sweetened beverages, and alcoholic beverages was similar between both groups
(p>0.05).9 Further, mean caloric, carbohydrate, protein, fat, and vitamin intake was similar
between groups (p>0.05).9 As a percentage of total calories, individuals with FGIDs consumed a
higher percentage of calories from fat, saturated fat, and monounsaturated fat compared to
controls (p<0.05); however, there was no difference in the percentage of calories from
polyunsaturated fats (p>0.05).9 When assessing consumption of bioactive substances, there were
no differences in the amount of serotonin-containing or tryptophan-containing foods (p>0.05).9
Consumption of epinephrine-containing foods (chocolate, nuts, bananas, oranges, and raisins)
was slightly higher in FGID individuals compared to controls (57% vs 45%); however, the
difference was not statistically significant (p=0.10).9 Although limited research is available, the
results of this study suggest that the diet of individuals with GI symptoms is similar to the diet of
individuals without GI symptoms. Interestingly, individuals with FGIDs had similar
consumption of foods that are commonly thought to cause GI upset (i.e. lactose, wheat, and
fructose).9
In contrast to the above study, Torres et al evaluated the diets of 1,870 individuals
formally diagnosed with irritable bowel syndrome (IBS) compared to 34,578 healthy individuals
(controls) using three 24-hour recalls that were administered randomly over a 6-month period.10
IBS is a gastrointestinal disorder characterized by abdominal pain and altered bowel habits
(diarrhea, constipation, or mixed).10 Individuals with IBS had a lower consumption of milk
(p<0.0001), yogurt (p=0.001), and fruits (p<0.001) compared to controls.10 Individuals with IBS
had a higher total caloric intake compared to controls (p<0.001) and IBS subjects were more
likely to consume the recommended dietary fiber intake (25g/day) compared to control subjects
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(p=0.07).10 It is generally assumed that there is a positive correlation between certain dietary
habits and gastrointestinal upset, however, as the above research studies suggest, there is a high
level of heterogeneity in the specific dietary factors that contribute to GI upset. 10 Other factors,
such as the human gut microbiome, can influence the GI tract and the presence of GI symptoms.
The Human Gut Microbiome
Schippa et al. compares the human gut microbiome to the intricacy of a fingerprint.
Similar to a fingerprint, the colonic microbiome is complex and varies from person to person.11
The colonic microbiota can contain over 100 different bacterial phyla; further, the composition
of the microbiota changes based on one’s diet, weight status, environment, geographical location,
and health status (i.e. inflammatory and disease status). Understanding these factors allows
researchers to better understand the components of a symbiotic, or healthy, gut microbiome as
well as the components of a dysbiotic, or imbalanced, microbiome.
Core Microbiome
Research shows that the microbiome can be generalized to an extent. For example,
Backhed et al found that the human gut microbiome is dominated by two phyla- Bacteroidetes
and Firmicutes.12 Zupancic et al supported the predominance of Bacteroidetes and Firmicutes in
the colonic microbiome and also found a significant correlation between the Bacteroidetes:
Firmicutes ratio and age and sex-adjusted BMI (p=0.04).13 That being said, Zupancic et al
observed significant differences in the concentration of both dominant and rare genera in 95%
of subjects.13 By sequencing 16S rDNA, Schippa et al supported Zupancic’s research. Schippa et
al found that the majority of bacterial species detected in the gut belong to the Bacteroidetes and
Firmicutes phyla.11 Mariot et al observed an average ratio of 10.9 of Firmicutes to Bacteroidetes
in the fecal microbiota of adults.14 The ratio of Firmicutes to Bacteroidetes is thought to be an
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indicator of gut microbial health.15 Typically, Firmicutes represent 60-80% of the total bacteria
within the gut while Bacteroidetes represent 15-30% of the total bacteria within the gut.15
According to Harmsen et al and Mariat et al, anaerobic fecal bacterial can also be divided
into two groups by genus: dominant and subdominant.14,16 Dominant anaerobic fecal bacteria,
which are >109 coliform forming units (CFUs)/gram, include Bacteroides, Eubacterium,
Bifidobacterium, Peptostreptococcus, Ruminococcus, Clostridium and Propionibacterium.14,16
Subdominant anaerobic fecal bacteria, which are <10 9 CFUs/gram, include Streptococcus,
Enterococcus, Lactobacillus, Fusobacterium, Desulfovibrio and Methanobrevibacter as well as
certain bacteria from Enterobacteriaceae family, particularly Escherichia coli.14,16
Despite the diversity of bacterial species, Schippa et al and Turnbaugh et al argue for a
common core gut microbiome, or set of functions that are shared by the majority of gut microbial
genes.11,17 Functions of these core genes include the synthesis of short-chain fatty acids (SCFAs),
amino acids and vitamins, as well as the degradation of polysaccharides.11,17
Microbial Profile of GI Upset
Physiological etiologies that may lead to GI symptoms include abnormal GI motility,
visceral hypersensitivity (heightened pain within viscera), immune dysregulation, inflammation,
mucosal barrier dysfunction, alterations in the gut microbiome, dietary intake and variety,
maldigestion or malabsorption of nutrients, as well as the amplification or disruption of the gutbrain axis.18 For the purpose of this review, GI symptoms are discussed in relation to the colonic
microbiome and in relation to dietary intake. Alterations of the gut microbiome may not only
contribute to GI upset, but GI symptoms may also be a reflection of an altered microbiome.
In a cross-sectional study, Zhu et al found that children with constipation had a
significantly different microbial profile compared to children without constipation. Children with
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constipation had a significantly higher proportion of several different Firmicutes.19 Mancabelli et
al similarly found that adults with functional constipation (FC), defined as having three or less
bowel movements per week, have a different fecal microbiota composition compared to healthy
subjects (HS).20 At a phyla level, FC and HS participants both had an predominance of
Bacteroidetes and Firmicutes; however, the abundance differed between groups. At a genus
level, FC participants exhibited increased average relative abundance of Bacteroides (34.25%) ,
Faecalibacterium (6.85%), Alistipes (6.48%), and Lachnospira (4.44%) bacteria.20 HS subjects
also had increased relative abundance of Bacteroides (45.23%) and Alistipes (5.34%). The
researchers did not find a specific microbial biomarker associated with functional constipation. 20
That being said, HS participants had a higher concentration of Bacteroides (p=0.0004),
Roseburia (p=0.006), and Coprococcus (p<0.01), while FC subjects had higher concentrations of
Faecalibacterium (p=0.0001) and other genera of the Ruminococcacae family. 20
Mancabelli et al then selected 10 participants, 5 FC and 5 HS, and performed Ilumina
shotgun sequencing.20 The data collected from shotgun sequencing the samples was used to
compare microbial pathways between FC and HS subjects using the MetaCyc database. The
researchers found a significant difference in 629 metabolic pathways. HS individuals had a
higher number of genes associated with carbohydrate and fatty acid metabolism (p<0.05)
compared to FC subjects. These pathways influence the production of SCFAs and may provide a
defense for the etiology of functional constipation based on one’s gut microbiome. In contrast,
FC subjects had a higher abundance of methanogenic pathway genes, meaning FC subjects have
a predicted higher capacity to produce hydrogen compared to HS subjects (p=0.05).20
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Individuals with diarrhea also display an altered gut microbial distribution. Samb-Ba et al
found that adults with diarrhea had a significantly higher number of bacterial species per stool
sample compared to adults without diarrhea; however, the individuals with diarrhea had lower
proportions of Bacteroides ssp. (including Bacteroidetes vulgatis) in comparison.21 This is
supported by Chang et al in a study that evaluated the fecal microbiota of adults with Clostridium
difficile associated diarrhea through analysis of 16S rRNA gene sequences. 22 Chang et al found
that the majority of gene sequences from the control subjects were from the Bacteroidetes and
Firmicutes phyla; however, individuals with C. difficile, an opportunistic pathogen, had an
altered distribution of the 16S phylotypes, indicating a deviation from what is recognized as the
“normal” microbiome.22
Nutrients and the Gut Microbiome
The composition of the human gut microbiota is strongly influenced by the composition
of one’s diet. Roughly eight hours after consuming a meal, undigested chyme, primarily
indigestible polysaccharides, resistant proteins, water and electrolytes as well as endogenous
mucins and enzymes, enter the large intestine for further digestion and absorption.23 Within the
colon, water and electrolytes are rapidly absorbed, microbial fermentation occurs, and feces are
formed and stored. A diverse microbial community known as the gut microbiome, works to
salvage energy and absorbable nutrients, feed the intestinal epithelial cells, and protect the host
against invasion by pathogenic organisms.23 The composition of the gut environment directly
affects colonic transit time, pH, osmolarity, and gas production.24
Carbohydrates are the major substrates that influence the colonic microbiome. While the
majority of carbohydrate digestion and absorption occurs in the small intestine, certain
carbohydrates bypass the small intestine and enter the large intestine undigested. These
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carbohydrates include plant cell wall polysaccharides (cellulose, arabinoxylan, xyloglucan, bglucan, mannan, pectins and lignin), resistant starch, inulin, fructo-oligosaccharides, simple
sugars and sugar alcohols.24 Some plant cell-wall polysaccharides, such as cellulose and lignin,
are only partially digested in the large intestine, while hemicelluloses and pectins undergo more
complete breakdown by colonic bacteria.23 As an example, Dongowaski et al found that cultures
of Bacteroides thetaiotaomicron isolated from human fecal flora first degraded pectin to
oligogalacturonic acids and then completely fermented the oligogalacturonic acids to SCFAs and
gases within 24 hours in vitro.25
Fructans (i.e. inulin and fructo-oligosaccharides (FOSs)), found naturally in certain fruits
(bananas), vegetables (garlic, onions, artichokes), and grains (wheat, barley), have been shown to
stimulate the growth of beneficial bacteria in the colon.26 As such, inulin and FOSs, are
commonly referred to as prebiotics. Research shows that different prebiotics have varying
capabilities to stimulate the growth of bacteria within the gut. Scott et al demonstrated that shortchain FOS were able to stimulate the growth of several Firmicutes, Actinomycetes, and
Bacteroidetes, including Roseburia, Bifidobacterium, and Bacteroides species; however, many
bacteria were unable to utilize long-chain FOS (inulin) for growth.26
Unabsorbed sugars and sugar alcohols can also be used as substrates for fermentation in
the large intestine. In a randomized-crossover study conducted by Vogt et al human subjects
ingested 25g of L-rhamnose, lactulose, or d-glucose per day for 28 days.27 Results from the study
showed that L-rhamnose significantly increased serum propionate when compared to lactulose
(p<0.05), while lactulose supplementation raised the serum acetate: propionate ratio (p<0.005).27
Both results indicate fermentation of 6-carbon sugars; however, the specific microbes
responsible for fermentation were not assessed.27 Different phyla, species, and strains of bacteria
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ferment different carbohydrate sources, and, as a result, produce different end-products.
Identifying typical carbohydrate sources through use of food recalls can allow researchers to
identify the amount and types end-products produced to potentially exert beneficial effects to the
host.
Short Chain Fatty Acids
Production and Absorption
Short-chain fatty acids (SCFAs) are the primary end-products of anaerobic bacterial
fermentation in the colon. The three major SCFAs – acetic acid (C2), propionic acid (C3), and
butyric acid (C4) (structures shown in Table 1) – are produced via carbohydrate fermentation
and represent 90-95% of the SCFAs produced in the large intestine.28 Acetate, propionate, and
butyrate are typically produced in a 3:1:1 ratio.28 Select branched chain fatty acids are also
produced via proteolytic breakdown of valine, leucine, and isoleucine.
There is no single metabolic pathway for the production of SCFAs, rather several
pathways are used depending on the colonic microbiota composition, the substrates available for
fermentation, and other environmental conditions (i.e. colonic pH and level of CO2 production).
These pathways are important to document in order to understand ways to modulate and increase
SCFA production by enteric bacteria. This section discusses the metabolic pathways utilized in
relation to the end-product produced- acetate, propionate, or butyrate.
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Table 1: Properties of the Three Major SCFAs29,30
Fatty Acid

Structure

Acetic Acid

CH3 – COOH

Molecular
Boiling
Weight
Point (C)
(g/mol)
60.05
118

Propionic Acid

CH3 – CH2 – COOH

74.1

Butyric Acid

CH3 – (CH2)2 –COOH

88.1

Melting
Point (C)

Density

16.6

1.08

141

-20.7

0.99

163.5

-5.7

0.96

Acetate is the most abundantly produced SCFA and constitutes more than 50% of the
SCFA composition in feces.30 Acetic acid’s structure is a carboxylic acid bonded to a single
methyl group (Table 1) (Acetate: CH3 – COO-). Approximately one-third of acetate is produced
by acetogenic bacteria.28 Acetogenic bacteria generate acetate from hydrogen and carbon dioxide
or from formate via the Wood-Ljungdahl pathway.29 Through the Wood-Ljungdahl pathway, one
molecule of glucose will produce 3 molecules of acetate.30 That being said, the majority of
acetate is produced by colonic anaerobes through fermentation of carbohydrates from acetylCoA.31 Anaerobes that produce acetate also utilize reducing equivalents to produce other
products such as succinate, propionate, butyrate, formate, d-lactate, l-lactate, and ethanol.28
Propionic acid’s structure is a carboxylic acid bonded to a methylene group bonded to a
methyl group (Table 1) (Propionate: CH3 – CH2 – COO-). Colonic bacteria utilize three pathways
to produce propionate: the succinate pathway, the acrylate pathway, and the propanediol pathway
(Figure 2).28,31,32 The succinate pathway is the most widely utilized pathway by Firmicutes,
Negativicutes and Bacteroidetes, to produce propionate.31 In this pathway, oxaloacetate from
pyruvate goes through the TCA cycle to produce succinate as a substrate for the formation of
propionate. The decarboxylation of methylmalonyl-CoA to form propionyl-CoA is specific to the
succinate pathway.32 The second pathway used to produce propionate is the acrylate pathway. In
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this pathway, lactoyl-CoA dehydratase and enzymatic reactions convert lactate to propionate.31
This pathway is utilized by very few Firmicutes (Veillonellaceae and Lachnospiraceae
families) and is not thought to produce a significant amount of propionate in the colon.31,32
Distinct Firmicutes and Proteobacteria produce propionate via the propanediol pathway.28 The
propanediol pathway is characterized by the conversion of deoxy-sugars (i.e. fucose and
rhamnose) to propionate.28,31,32 Salonen et al conducted a study to evaluate the effects of dietary
interventions on SCFA production and bacterial communities.33 The researchers saw that an
increase in fecal Bacteroidetes concentration positively correlated to fecal propionate
concentrations.33 This research suggests that Bacteroidetes (using the succinate pathway) are the
primary producers of propionate in humans.
Butyric acid’s structure is a carboxylic acid bonded to two methylene groups bonded to a
methyl group (Figure 1) (Butyrate: CH3 – CH2 – CH2 – COO-). In the colon, butyrate is produced
by gram-positive Firmicutes, most abundantly Eubacterium rectale/ Roseburia spp. and
Faecalibacterium prausnitzii.34 The primary pathway in which enteric bacteria produce butyrate
is the butyryl-CoA: acetate CoA-transferase pathway (see Figure 1).28, 31,34 In this pathway
butyryl-CoA is produced form Acetyl-CoA. A single enzymatic reaction then converts butyrylCoA to butyrate.31 A less common pathway is the butyrate kinase pathway in which
phosphotransbutyrylase and butyrate kinase enzymes convert butyryl-CoA into butyrate.28,31
SCFA concentration in feces represents ~5% of the total concentration of SCFAs that are
produced in the colon, while ~95% of the total SCFAs are rapidly absorbed and utilized by
colonocytes or are put into systemic circulation. SCFAs are absorbed in the human colon and
cecum at a comparable rate to that of the colonic and cecal mucosa of rats, with a higher rate of
uptake seen in the distal colon compared to the proximal colon.35,36 Ruppin et al perfused the
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colon of healthy individuals with an isotonic solution containing 0-90 mM of SCFAs and found
that transport of SCFAs across colonocytes into circulation was primarily concentration
dependent.37 The study identified two mechanisms of colonic SCFA absorption: simple diffusion
of protonated SCFAs along with consumption of CO2 (~60% of SCFAs), and cellular uptake of
ionized SCFAs along with ionic diffusion of sodium and potassium.35,37,38
While the absorption of SCFAs is similar, the distribution and fate of SCFAs differ.28
Oxidation of SCFAs, particularly butyrate, supplies 60-70% of the energy needs of colonocytes
(even in the presence of glucose and glutamine which can also serve as substrates for
colonocytes).35 Since butyrate is primarily utilized by epithelial cells, systemic circulation levels
of butyrate are relatively low (1-3 mM).28,39 Propionate is primarily metabolized in the liver and
peripheral blood concentrations of propionate are typically low (1-3mM).28,39 Acetate is the only
SCFA to reach high concentrations in peripheral blood (100-150 mM). It is estimated that
SCFAs constitute 5-10% of the average person’s total metabolizable energy per day. 39
Physiological Effects
The role of the human microbiome in overall health is a major topic of current research;
however, the mechanisms linking the microbiome to health status are largely unknown. Research
suggests that a dysbiotic microbiome plays a causative role in several health conditions (e.g.
metabolic disorders and inflammatory bowel disease).40,41 At the same time, a symbiotic
microbiome is thought to protect against western diseases.40,41 It’s hypothesized that SCFAs may
be the metabolic link between the human microbiome and health status.
Both butyrate and propionate have been shown to inhibit histone deacetylases
(HDACs).42 By inhibiting HDACs, butyrate is able to regulate gene expression and cellular
differentiation. This suggests that butyrate may have an anti-carcinogenic effect in colonic
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epithelial cells.28,41,42 Interestingly, butyrate has been shown to increase the proliferation of
healthy colonocytes, thereby maintaining/ improving gut integrity; however, in the presence of
transformed cells (cancerous colonocytes), butyrate induces terminal differentiation and
apoptosis.43 This is because glucose is the primary fuel source for cancerous colonocytes (in
normal colonocytes butyrate is the primary fuel source).43 As glucose is utilized by colonocytes,
butyrate accumulates and functions as a HDAC inhibitor.43
Acetate, propionate, and butyrate have also been shown to signal to free fatty acid
receptors 2 and 3 (FFAR2, FFAR3), which are G-coupled protein receptors.39 Karaki et al
demonstrated that FFAR2 is expressed in enteroendocrine cells in the ascending colon in
humans.44 Further, activation of FFAR2 by SCFAs has been shown to facilitate/ modify peptide
tyrosine tyrosine (PYY) secretion.39 PYY is a hormone that reduces appetite. Greenway et al.
conducted a study to evaluate the effects of fermentable carbohydrates on PYY levels in healthy
overweight and obese individuals.45 After 28 weeks, the researchers saw a significant increase in
PYY and satiety 1-hr postprandial compared to baseline measurements (p<0.01).45 This research
supports that SCFAs signal to FFAR2 and 3 receptors to increase secretion of PYY in the gut. As
a result, increasing SCFA production may play a role in appetite regulation, which can be useful
in the management of chronic diseases such as metabolic syndrome and overweight/obesity.
SCFAs also act as mediators of intestinal and systemic immune function by inhibiting
HDACs and by activating G-coupled protein receptors of leucocytes and endothelial cells.46
SCFAs suppress lipopolysaccharide (LPS) and cytokine stimulated production of proinflammatory markers (i.e. tumor necrosis factor- alpha, interleukin-6, and nitric oxide).
Butyrate, in particular, been shown to enhance the release of interleukin-10, an antiinflammatory cytokine.46 Nastasi et al demonstrated that butyrate and propionate exert an
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immunomodulatory effect by influencing gene expression in immature and mature human
monocyte-derived dendritic cells.47 In the study, the researchers saw that propionate and butyrate
inhibited the expression of LPS induced cytokines (IL-6 and IL-12).47 Further, the release of proinflammatory chemokines (CCL3, CCL4, CCL5, CXCL9, CXCL10, and CXCL11) was
significantly reduced following exposure.47 SCFAs also modify lymphocyte function by
inhibiting T-cell proliferation, by reducing the production of pro-inflammatory cytokines, and by
producing regulatory T-cells. SCFAs have been shown to improve inflammatory conditions such
as inflammatory bowel disease, sepsis, and ischemia induced injury.45
Probiotics
Definition and Strains
Probiotics, as defined by the world health organization, are live microorganisms that,
when provided in adequate amounts, exert a beneficial effect to the host.48 Probiotics include
several strains of Lactobacilli and Bifidobacteria as well as Escherichia coli strain Nissle 1917,
Saccharomyces boulardii, and Streptococcus thermophilus.49 Probiotics are naturally found in
yogurt, cheese, sauerkraut, kombucha, kefir, and kimchi. Animal and human studies show that
probiotics can be supplemented to reduce diarrhea, prevent bacterial infections, manage
gastrointestinal diseases, alleviate lactose intolerance and other allergies, and have anti-cancer
effects; however, not all probiotic strains can be generalized to have these effects.50
When considering the health benefits of probiotic supplements, several factors should be
considered. For example, monostrain probiotics (single strain supplements) may have different
effects compared to multistrain/multispecies supplements. Timmerman et al evaluated the
survivability and activity of a multispecies culture collection containing five strains of
Bifidobacterium (bifidum, breve, infantis, lactis, and longum), nine strains of Lactobaccillus
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(acidophilus, brevis, bulgaricus, casei, helveticus, paracasei, plantarum, rhamnosus, and
salivarius), as well as Enterococcus faecium, Lactococcus lactis, and Streptococcus
thermophilus.51 Timmerman et al found that multispecies probiotics have increased functionality
and efficacy in vivo compared to monostrain probiotic cultures.51 The researchers also found that
different strains of probiotics exert different effects. Timmerman et al argue that B. bifidum, Lc.
lactis, L. acidophilus and L. casei are potent immunomodulators while B. infantis, L. plantarum,
L. rhamnosus and L. salivarius exhibit strong antimicrobial activity.51 That being said, there are
currently no guidelines regarding the number of probiotic strains that are optimal for
colonization and efficacy. Timmerman et al argues that certain strains, when encapsulated
together, exert synergistic effects; however, certain strains, when incorporated into a multi-strain
supplement, may inhibit the activity of other strains, thereby reducing the effectiveness of the
multi-strain probiotic.51
Probiotic strains used in supplements must be stable enough to withstand manufacturing,
processing, storage, and transport. Additionally, the efficacy of a probiotic strain is dependent on
its survivability in the presence of gastric juice in the stomach as well as enzymes and bile salts
in the intestine.52 Time of probiotic exposure to these factors, degree of stomach acidity, and the
concentration of bile salts will also affect viability of probiotics. 52 Research suggests resistance
to these factors is strain-dependent.52 For example, Madureira et al evaluated the survivability
and stability of several strains of B. animalis, L. acidophilus, L. paracasei, and L. brevis when
exposed to gastrointestinal conditions.53 Madureira et al found that all of the strains tested
maintained their viability upon exposure to hydrochloric acid and pepsin (gastric juice);
however, L. paracasei ssp. Paracasei LCS-1 and B. animalis BLC-1 experienced a severe
decrease in viable cell numbers upon exposure to bile salts.52,53
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Another significant factor affecting the efficacy of the probiotic supplement is the amount
of colony forming units (CFUs) per capsule. The standard probiotic dose thought to be necessary
to exert beneficial effects to the host ranges from 107 to 109 CFUs/mg/day.54 That being said,
processing, storage, and gastrointestinal conditions will alter the CFUs of a given strain,
affecting the strain’s survivability and overall effectiveness. Research suggests that >10 6
CFUs/mL in the small intestine and >108 CFU/g in the colon is necessary to obtain clinically
significant effects.54 The appropriate probiotic dosage will vary depending on the strain being
supplemented, the frequency of supplementation, and the condition for which the probiotic is
being supplemented. For example, in the management of acute infectious diarrhea, research
suggests that a higher dosage is more effective than a lower dosage; however, higher dosages
(>1010 CFUs/g) may not be necessary in the management of chronic conditions.54 Probiotic
effects are likely dose-dependent and greater than 10 7 to 109 CFUs/mg/day is generally
considered the effective dose in humans.54
The physiological effects and overall efficacy of a probiotic supplement depends on each
of these factors; however, the safety of the probiotic should also be considered. It is generally
assumed that probiotics have an “acceptable known safety profile”; however, numerous genera,
species, and strains are included under the umbrella term, probiotic, making it difficult to provide
a safety assessment statement for all probiotics.55 Rather, probiotic safety should be determined
on a strain-by-strain basis. Well-known and commonly used strains, such as Lactobaccillus,
Bifidobacterium, and Saccharomyces have been determined to be safe for consumption for the
general population; however, the manufacturing of the supplement can still impact the product’s
overall safety.55 Low quality probiotic supplements should not be used in research and should
not be recommended for consumption. Rather, only supplements that are made with Current
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Good Manufacturing Practices (CGMP) and products that are Generally Recognized as Safe
(GRAS), should be recommended and consumed.55 As a component of CGMP, probiotic
supplements should also meet purity standards and should be manufactured under a quality
management system.55
Mechanism of Probiotic Action
Probiotics exert health benefits by influencing the composition and function of
commensal microbiota, by altering host epithelial and the immune system, and by combating
microbial and food toxins that adversely affect human health. That being said, the mechanism by
which probiotics exert their ‘beneficial effect to the host’ is not well understood, this is most
likely because probiotics do not have just one mechanism of targeted action. Mechanisms
documented in literature include influence on gut barrier function, production of inhibitory
substances, immune effects, blockage of adhesion sites, gut microbiota modulation,
antiproliferative effects, competition for nutrients, and degradation of toxin receptors (Figure
2).50
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Figure 1: Mechanism of Probiotic Action50
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One of the main effects of probiotics is colloquially referred to as “killing the bad
bacteria.” While probiotics accomplish this through several mechanisms, one of the primary
mechanisms is the production of antibacterial inhibitory substances, such as bacteriocins, organic
acids, and hydrogen peroxide.50 Bacteriocins are peptides that are active against other bacteria
most commonly by inhibiting cell wall synthesis and by destroying target cells by pore
formation.50,56 Different strains of probiotics typically produce different bacteriocins. For
example, Corr et al. found that Lactobacillus salivarius UCC118 produces bacteriocin Abp118. 57
Bacteriocin Abp118 has an antagonist effect against Listeria monocytogens and directly protects
mice induced with Listeria monocytogens against infection.57 Bacteriocins produced by
lactobacilli and Bifidobacteria have been shown to inhibit several pathogens, including E. coli,
Heliobacter pylori, Listeria monocytogens, Rotavirus, and E. coli. 50 Bacteriocins and organic
acids such as lactic acid and SCFAs (byproducts of probiotics) also lower the pH within the GI
tract. While lactic acid producing bacteria such as lactobacilli and Bifidobacteria can survive
well in an acidic environment, many pathogenic bacteria cannot.
Another mechanism of probiotic efficacy is the ability to block adhesion sites for
pathogen bacteria.50 Probiotic strains compete for adhesion sites along the epithelial surface of
the gastrointestinal tract, inhibiting the colonization of pathogenic bacteria, causing pathogens to
pass through the GI tract for excretion. Acid-resistant probiotics (i.e. Bifidobacterium longum
and Bifidobacterium catenulatum) have demonstrated better adhesion to the epithelial surface
compared to acid-sensitive strains. Additionally, multi-strain probiotics (i.e. VSL#3) can
modulate gene expression and improve the adhesion of bacterial cells to the GI tract.
Health promoting bacteria also compete more efficiently for nutrients, which prevents
pathogen’s growth and proliferation. For example, while iron is an essential nutrient needed for
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the survival of most bacteria, it is not needed for lactobacilli bacteria. Additionally, certain
strains of Lactobacilli, such as L. acidophilus and L. delbrueckii, can bind ferric hydroxide at
their cell surface, making iron less available for pathogens. This essentially creates an
environment in which certain pathogens cannot survive.50
Probiotics may also have anti-proliferative effects, as indicated in recent research. Certain
probiotics are able to metabolically inactivate mutagenic substances, while others can bind
heterocyclic aromatic amines and N-nitroso compounds to reduce DNA damage and levels of
cancer-causing compounds.50 Additionally, probiotics influence on cytokine production and Tcell function may promote anti-tumor activity by amplifying the immune response of tumor
tissue.50 Research also shows that enhanced levels or lactobacilli and Bifidobacteria and lower
amounts of Clostridium, coliforms, and Bacteroides are associated with reduced incidence of
colorectal cancer.50
Therapeutic Effects of Probiotics on GI Upset
Probiotics likely have an indirect influence on SCFAs by enriching specific gut microbial
populations that preferentially ferment carbohydrates.49 Meimandipour et al. found that
supplementation of Lactobacillus agilis and Lactobacillus salivarius significantly increased
production of lactate, propionate, and butyrate in vitro in cecal microflora of chickens.58 Another
in vitro study conducted by Ogawa et al. showed that specific Lactobacillus species (L. casei and
L. acidophilus) inhibited growth and activity of Shiga toxin-producing Escherichia coli
O157:H7, a pathogenic bacterium.59 In vitro studies suggest that probiotics exert a positive effect
on the microbiome by promoting the colonization of beneficial bacteria and by inhibiting the
growth of opportunistic pathogens, both of which have an indirect effect on SCFA production. In
vitro studies are beginning to be supported by human randomized controlled trials (RCT). In an
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RCT conducted by Wang et al. the researchers supplemented 6.0 x 10 10 CFUs/day of
Lactobacillus plantarum to healthy individuals for four weeks.60 Fecal concentrations of
Bifidobacterium significantly increased (p<0.05), concentrations of Desulfovibrio (an
opportunistic pathogen) significantly decreased (p<0.05), and acetate and propionate
concentrations significantly increased (p<0.05) after 4 weeks of supplementation.60
Prebiotics
Definition and Sources
A prebiotic is a food ingredient not digested in the upper GI tract that selectively
stimulates the growth and/or activity of one or a limited number of bacteria in the colon.49
Prebiotics also reduce non-beneficial (pathogenic) bacterial populations. Prebiotics include
inulin, fructo-oligosaccharides, and resistant starch and are naturally found in foods such as
beans, peas, oats, onions, garlic, tomatoes, and bananas. Fibers that act as prebiotics include
cellulose, lignin, hemicellulose, pectins, and fructans (i.e. fructo-oligosaccharides and inulin).
Therapeutic Effect of Prebiotics on GI Upset
Numerous studies have documented the potential of prebiotics to increase SCFA
production. Cardelle-Cobas et al demonstrated that galacto-oligosaccharides (GOS) stimulated
Bifidobacteria growth and increased production of acetic acid in human fecal cultures (in
vitro).61 In a similar study using fecal inocula incubation, Hernot et al found that short-chain
oligosaccharides (e.g. NutraFlora, GTC Nutrition, Golden) were more rapidly fermented
compared to long-chain oligosaccharides (e.g. inulin- Beneo ST and HP).62 In vitro, Lactobacilli
concentrations increased similarly amongst short and long-chain oligosaccharides; however,
Bifidobacteria concentrations significantly increased when short-chain oligosaccharides were
fermented.62 The increase in Bifidobacteria was accompanied by an increase in gas, acetate and
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propionate production in short-chain oligosaccharides.62 In a pilot human study conducted by
Schwiertz et al, supplementing 15 grams of resistant starch per day for 28 days resulted in a
significant increase fecal butyrate concentrations; however, total SCFA concentration remain
unchanged.63 The research conducted by Cardelle-Cobas, Hernot, and Schwiertz suggest that
prebiotics directly impact SCFA production.61,62,63 Further, prebiotic chain length influences
fermentation rates, gas production, and microbial profiles.49
Synbiotics
Synbiotics are combination probiotic and prebiotic supplements. Many researchers
hypothesize that synbiotics enhance colonic fermentation and promote gut symbiosis at a greater
level than probiotics or prebiotic supplements that are administered alone.49,64 Grela et al
conducted a study to evaluate the effects of multi-strain probiotics alone (Lactococcus lactis,
Carnobacterium divergens, Lactobacillus casei, Lactobaccillus plantarum, and Saccharomyces
cerevisiae), prebiotics alone (inulin), or both probiotics and prebiotics on select markers of the
gastrointestinal system, including SCFA concentrations, in pigs.65 The concentration of
propionic, butyric, and valeric acids increased significantly in the prebiotic group and in the
prebiotic plus probiotic group when compared to a control group (p<0.05).65 A similar study was
conducted in healthy individuals by Worthley et al (34). The researchers did not observe a
significant change in SCFA concentrations in the probiotic group (Bifidobacterium lactis), the
prebiotic group (high-amylose maize starch), or the synbiotic group (probiotic + prebiotic) after
4 weeks.64 More research is needed to understand the effects of synbiotics on SCFA
concentration in humans based on the above study and a general lack of available human
research on synbiotics. That being said, results from studies on prebiotic and probiotic
supplementation alone support the use of probiotics and prebiotics for the modulation of SCFAs.
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Enzymes
Digestive enzymes include proteases, peptidases, lipases, amylases, nucleases, cellulases,
and lactase. Digestive enzymes speed up and improve the breakdown of macromolecules (fats,
carbohydrates, and proteins) into smaller molecules that are more easily absorbed. 66 In addition
to probiotics and prebiotics, digestive enzymes may improve gastrointestinal symptoms and may
modulate the gut microbiome. Spagnuolo et al evaluated the effects of combination -glucan,
inositol, and digestive enzyme supplementation on gastrointestinal symptoms of individuals with
IBD and IBS.66 The researchers found a significant reduction in the intensity of abdominal pain
(p<0.01), bloating (p<0.001), and flatulence (p<0.005) over 4 weeks; however the group did not
experience any significant changes in inflammatory markers during the study. 66 In another study
conducted by Quinten et al, individuals with common gastrointestinal problems randomly
received either domperidone (n=19) or Similase total (n=43).67 Similase total is an enzyme
supplement that contains protease, cellulase, amylase, alpha galactosidase, maltase, lactase,
lipase, invertase, and phytase, while domperidone (Motilium) is a common antiemetic and
prokinetic medication for gastrointestinal disorders.68 Quinten et al found that participants
receiving Similase total experienced a more significant reduction in abdominal pain compared to
those receiving domperidone after 5 days of treatment (p=0.021).67
In addition to improving gastrointestinal symptoms, digestive enzymes may influence the
gut microbiome, however research is limited and nascent in this area. Nishiyama et al divided
mice into two groups- the control, who received tap water, and the treatment group, who
received lipase, amylase, and protease.69 The mice that received the enzyme treatment had a
significantly different microbiota after 21 days.69 Specifically, treated mice had a higher
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abundance of Akkermansia muciniphila and Lactobacillus reuteri, two beneficial commensal
bacteria, in the cecum.69
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CHAPTER 3
MATERIALS AND METHODS
Participant Selection
Potential participants responded to a flyer advertised at East Tennessee State University
sent through a mass email to students, faculty, and staff, or through advertisement at Johnson
City health food stores, Johnson City community/ senior centers, and other retail establishments
(See Appendix A). Potential participants were then screened for eligibility using a phone
interview (See Appendix B). Participants met the following criteria of inclusion (1) self-reported
presence of GI symptoms greater than 3 times per week (i.e. abdominal pain, heartburn, acid
regurgitation, bloating, nausea and vomiting, abdominal distension, burping, increased gas,
decreased passage of stools, increased passage of stools, loose stools, hard stools, urgent need for
defecation, feeling of incomplete evacuation), (2) self-identified as healthy or having few health
complications, and (3) over the age of 18 years old. Criteria of exclusion included (1) under the
age of 18 years old, (2) diagnosis of Celiac disease, irritable bowel syndrome, inflammatory
bowel disease (including Crohn’s disease and Ulcerative Colitis), (3) previous use/ consumption
of GlutenShield, (4) current consumption of any prebiotics, probiotics, enzymes, non-steroidal
anti-inflammatory drugs (NSAIDS), fish oil, and/or fiber supplements unless the participant was
willing to halt use 2 weeks prior to beginning the study), (5) Recommendation/ prescription use
of any NSAID, and (6) pregnancy or intention to become pregnant within 60 days.
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Study Design
The study was a split, 28-day randomized, partially blinded design. Eligible participants
were administered an informed consent document by the principal investigator. After completing
the informed consent, subjects were randomly assigned to one of two groups using a computer
random number generator. Group A completed a 2-week washout of any probiotics, prebiotics,
enzymes, NSAIDS, fish oil, and fiber supplements followed by a 28-day treatment period with
GlutenShield taken 3x/day with meals. Group B completed the same 2-week washout followed
by a 28-day placebo period with the placebo taken 3x/day with meals. Participants were blinded
to which group/ treatment they were given. Subjects were provided a procedure form and
materials to collect a stool sample at home when meeting to fill out the informed consent.
On day zero of the active study, subjects arrived at Hutcheson Hall at ETSU and
submitted a stool sample to the principal investigator. At this time, Dr. Kenneth Phillips
collected two tubes of whole blood. Participants also completed a food frequency questionnaire,
gastrointestinal symptoms questionnaire, and mood assessment on day zero. Participants were
provided either a bottle of GlutenShield or a bottle of placebo pills. Participants were then
instructed to take 3 pills per day with meals beginning on day 1 and lasting through day 28. On
day 28, participants came back to Hutcheson Hall at ETSU and submitted a second stool sample
to the principal investigator while Dr. Phillips again collected two tubes of whole blood.
Participants also completed the gastrointestinal symptoms questionnaire and the mood
assessment on day 28. Full review approval was obtained for this study by the ETSU
Institutional Review Board (IRB) on December 5, 2017; study number 1117.22f.
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Placebo and GlutenShield
The placebo for the study was prepared by Dr. Charles Collins in the ETSU college of
pharmacy. Each placebo capsule contained a 50/50 mixture of Avicel (cellulose) and of bentonite
powder (to have a similar color as GlutenShield). The placebo was encapsulated in Vcaps
Enteric and were made of cellulose.
GlutenShield is a combination probiotic, prebiotic, and enzyme dietary supplement.
Probiotics in GlutenShield include Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus
rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Lactobacillus brevis, Lactobacillus
salivarius, Streptococcus thermophilus, Bifidobacterium bifidum, Lactobacillus coagulans, and
Saccharomyces boulardii. Prebiotics in GlutenShield include Chitosan oligosaccharide,
fructooligosaccharides, alfalfa, Emblica officinalis extract, papaya juice powder, fulvic acid, and
ionic minerals. Enzymes in GlutenShield include dipeptyl peptidase IV (DPPV-IV), lactase,
cellulase, hemicellulase, xylanase, phytase, serrapeptase, and plant-based digestive enzymes
(lipase, protease, and amylase).
Assessments
Demographics and Food Frequency Questionnaire
On day 0 of the active trial, study participants completed NutritionQuest’s 2014 Block
Food and Activity Questionnaire, a food frequency questionnaire (FFQ). The form measured
usual dietary intake over the past month. Participants were instructed to report how often they
consume a given food (i.e. cold cereal- once a month, 2-3 times per month, once per week, 2
times per week, 3-4 times per week, 5-6 times per week, or every day), how much of the given
food they consume in a given day (i.e. 1 glass of orange juice, 1 cup of cold cereal), and what
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type of food they consume (i.e. low-fat, sugar-free). The questionnaire provided a detailed look
at typical consumption of:
•

Eggs and dairy foods

•

Cereals, grains, and breads

•

Vegetables

•

Fruits

•

Beans, tofu, and meat substitutes

•

Soups, mixed dishes, and noodles

•

Meat and chicken

•

Fish and seafood

•

Nuts, seeds, and snacks

•

Sweets and desserts

•

Spreads, sauces, and other foods

•

Beverages

From the self-reported intake, macronutrient and micronutrient intake was determined. In
addition to reported typical food intake, respondents self-reported sex, age, weight, and height,
from which body mass index (BMI) was calculated. Consumption of multiple and single
vitamins and minerals as well as typical physical activity and ethnicity were also recorded.
Gastrointestinal Symptoms Questionnaire
Participants completed the GI symptoms questionnaire on day 0, prior to the intervention,
and on day 29, after the intervention. The questionnaire measured the severity of GI symptoms
using a Likert numerical scale rating ranging from 1 (none) to 7 (always/severe) over the past
week. GI symptoms measured included abdominal pain/ discomfort, heartburn, acid
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regurgitation, bloating, nausea and vomiting, abdominal distension, eructation (burping),
increased gas, decreased passage of stools, increased passage of stools (rapid transit), loose
stools, hard stools, urgent need for defecation, and feeling of incomplete evacuation. The
questionnaire was based off of Catassi et al’s Solerno experts diagnostic criteria. 2 The
questionnaire was administered in paper-and-pencil formation and took 3-5 minutes to complete.
POMS Assessment
Participants completed MHS’s Profile of Mood States Second Edition adult short
assessment (POMS 2-A-S) on day 0, prior to the intervention, and on day 29, after the
intervention. The POMS short assessment was designed for adults ages 13 to 50+ and contained
a subset of 35 items taken from the full-length assessment. The assessment provided a cursory
evaluation of scaled scores for anger/ hostility, confusion/ bewilderment, depression/ dejection,
fatigue/ inertia, tension/ anxiety, vigor/ activity, and friendliness. The assessment was used to
evaluation changes in total mood disturbance at a given moment prior-to and following the
intervention. The assessment was self-administered in paper-and-pencil format and took 3-5
minutes to complete. Scores were measured using a t-score for each category that were
automatically calculated by MHS Online Assessment Center. A t-score of >70 indicated a very
elevated score, 60-69 indicated an elevated score, 40-59 indicated an average score, 30-39
indicated a low score, and <30 indicated a very low score (see Table 2).
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Table 2: POMS T-Score Classifications70
T-Score
70+

60-69

40-59
30-39
<30

Classification
Negative Mood State
Positive Mood State
Very Elevated Score (many
Very Elevated Score (Far
more concerns than are
fewer concerns than are
typically reported)
typically reported)
Elevated Score (more
Elevated Score (Fewer
concerns that are typically
concerns than are typically
reported)
reported)
Average Score (Typical
Average Score (Typical
levels of concern)
levels of concern)
Low Score (Fewer concerns
Low Score (More concerns
than are typically reported)
than are typically reported)
Very Low Score (Far fewer
Very Low Score (Many more
concerns than are typically
concerns than are typically
reported)
reported)

Blood Collection and Analysis
Dr. Kenneth Phillips, associate dean of research for ETSU’s college of nursing collected
10 mL of whole blood using a 23-gauge butterfly needle into two 8 ½ mL red-with-black top
Becton Dickinson vacutainers per participant on day 0, prior to the intervention, and on day 29,
post-intervention. The samples were put on ice and transported to ETSU’s health science
laboratory were allowed to clot at room temperature for 30 minutes. The clot was removed by
centrifuging the samples at 3000 x g for 10 minutes. One mL of the supernatant (serum) was
transferred into a 1.5mL polypropylene Fisherbrand micro-centrifuge tube using am Eppendorf
pipette. Two mL of serum was transferred to a 2.7 mL Fisher Scientific amber vial. The samples
were stored at -80 Celsius for future analysis. ELISA analysis was performed using
commercially available ELISA plates from Aviscera Bioscience. The remaining sample (2.7 mL)
was banked for future analysis.
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Fecal Collection
Following the informed consent meeting, participants were given a stool collection
procedure form and were told how to collect a stool sample (See Appendix C). Participants were
provided with saran (plastic) wrap, 4 self-sealing plastic bags, and 2 pairs of large nitrile gloves.
Participants were instructed to collected 2 stool samples- one on day 0, prior to the intervention,
and one on day 29, following the intervention. Participants collected the stool sample by lifting
the toilet seat and placing a layer of saran (plastic) wrap across the toilet, leaving a dip in the
middle. The bowel movement was then wrapped in the saran wrap, placed in a self-sealing
plastic bag, and frozen in the freezer. Participants then transported the stool sample to Hutcheson
Hall at ETSU on day 0 and day 29. Participants collected and froze the stool sample within 24hours of transporting the sample to ETSU. The stool samples were then stored on ice in a
biohazard cooler and were transported to the Human Nutrition and Dietetics Research
Laboratory on ETSU’s Valleybrook campus. At the laboratory, approximately 1 gram of fresh
sample was separated and stored at -80 Celsius for future PCR microbiome analysis. The
remaining sample was freeze-dried and used for nutrient analysis.
Fecal Analysis
Freeze Drying
The stool samples were freeze-dried using the FreeZone 2.5 Liter Freeze Dryer System.
The instrument and refrigeration switch were turned on and allowed to reach -40 Celsius. Once
-40C was reached, the vacuum was switched on and the instrument was ready for use. A 600
mL LABCONCO freeze dry flask and lid was weighed and the tare weight was recorded. The
pre-frozen stool sample was placed in the freeze-dry flask and the lid was sealed tightly. The
flask, lid, and sample were weighed and the weight was recorded. The stool sample weight (wet
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weight) was then calculated and recorded. The sample was place on the freeze-dryer and was
dried for ~48 hours at 0.077 mBar and -50 Celsius until all frost and cold spots were gone and
the sample was thoroughly dry. The sample was removed from the freeze dryer and the flask, lid,
and sample were weighed and the weight was recorded. The sample weight after freeze-drying
(dry weight) and the percent dry weight were then calculated. Samples were then ground to a
fine powder using an IKA M20 Universal Mill.
Table 3: Freeze-Drying Calculations
Freeze-Drying Calculations
Wet Weight
Dry Weight
Percent Dry Matter

(flask + lid + sample before) – (flask + lid)
(flask + lid + sample after) – (flask + lid)
Dry weight / Wet weight x 100

Kjeldahl Digestion
Total nitrogen was determined for freeze-dried and ground samples using kjeldahl
digestion. For the procedure, 100 mg of the sample was weighed (weight was recorded) into a
100 mL kjeldahl flask along with 1.9 grams of potassium sulfate (K2SO4), 80 mg of mercuric
oxide (HgO), 2 mL of concentrated (10N) sulfuric acid, and 2 porous boiling chips. The sample
was placed on LABCONCO heat mantle. The air was turned on and the mantle was turned to
heat setting 3. The sample refluxed for 8-12 hours, the heat mantle was then turned off, and the
sample was cooled to room temperature. 15 mL of deionized distilled water (DDW) was added
to the kjeldahl flask. The sample was brought to a boil and was filtered while hot into a 150 mL
Erlenmeyer flask using P5 grade Fisher brand qualitative grade plain filter paper circles.
Following digestion of the samples, distillation was performed to determine total nitrogen per
sample. The LABCONCO rapid distillation unit was turned on, set to heat setting of 6-7, and
was allowed to heat up. 5mL of 4% Boric acid and a few drops of kjeldahl indicator were added
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to a new 150 mL Erlenmeyer flask. The flask was placed at the bottom of the distillation unit.
The distillate (filtered sample) was added to the top of the unit and the Erlenmeyer flask was
rinsed with DDW. The material was emptied into the reaction tube. 10 mL of sodium thiosulfate
(NaOH/ Na2O3S2) was added to the top of the apparatus and was slowly emptied into the reaction
tube. The sample was allowed to distill for 15-20 minutes until the total volume of the boric acid
and ammonium solution reached 25-30 mL. During the distillation process, ammonium (NH4+)
was converted to ammonia gas (NH3+). NH3+ condensed into the boric acid solution to form
ammonium borate. The ammonium borate was then titrated with 0.1 N HCl until a color change
was observed (blue→red; base→acid). The mL of HCl needed to titrate the solution back to an
acid was recorded. Nitrogen per kilogram of sample and percent total protein were then
calculated. Samples were run in duplicate.
Table 4: Kjeldahl Calculations
Kjeldahl Calculations
Grams of Nitrogen per
Kilogram of Sample

(mL HCl titrated x 0.1N x 14.01) / weight of sample (grams)

Percent Total Protein

(g N per kg) x 6.25 / 1000g x 100

Total, Soluble, and Insoluble Dietary Fiber Analysis
Total dietary fiber (TDF), soluble dietary fiber (SDF), and insoluble dietary fiber (IDF)
was assessed on freeze-dried, ground stool samples using the automated ANKOM Dietary Fiber
Analyzer method AOAC 991.43.72 Reagents were prepared as shown in Table 5.
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Table 5: Fiber Reagent Methodology72
Reagent
78% ETOH
Enzyme Solutions
- -Amylase
- Protease
- Amyloglucosidase
MES-TRIS Buffer

Dilute HCl Solution (0.561N)

Method
Dilute 410.5 mL of 95% ETOH to 500 mL using DDW
water in a 500 mL volumetric flask.
Dilute 5 mL of -Amylase to 25 mL using DDW
Dilute 5 mL of Protease to 25 mL using DDW
Dilute 5 mL of Amyloglucosidase to 25 mL using DDW
Dissolve 9.76 g of 2-(N-Morpholino)ethansulfonic acid
(MES) and 6.1 g of Tris(hydroxymethyl)aminomethane
(TRIS) in 850 mL of DDW. Adjust pH to 8.2 using 6N
NaOH and dilute to 1 L with DDW
Dilute 23.375 mL of 6N HCl to 250mL in a volumetric flask
using DDW.

ANKOM IDF and SDF filter bags were labeled with a permanent marker. Each bag was weighed
using the Bag Weigh Holder and an AL54 Mettler Toledo analytical balance. The tare bag
weight was recorded onto a Dietary Fiber Data Spreadsheet (DFDS). One gram of Diatomaceous
Earth was weighed into two separate dishes. The weight of each was recorded onto the DFDS.
0.50.05 g of the freeze dried, ground stool sample was weighed in duplicate into two dishes.
The weight of each was recorded onto the DFDS. All fluid levels were checked on the DF
analyzer. The instrument and Nitrogen gas were turned on. SDF bags and Clamp Bar D were
installed on the instrument. Clamp Bar D was closed and the pre-weighed DE was added to each
SDF bag and was rinsed with 2-3mL of DI water. IDF bags and Clamp Bars B and C were
installed onto the instrument. Clamp Bar B was closed, pinching off the bags, and the preweighed samples were transferred to the IDF bags. SDF bags were hooked to Clamp Bar C.
Clamp Bar A was installed. The instrument was started, beginning the automated process of
digesting the sample. After the amylase and protease phases, the pH of the samples was checked
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and adjusted to 4.0-4.7 as needed with 0.561N HCl. After the automated process was complete,
IDF and SDF bags were rinsed with Acetone using the ANKOM Acetone Rinse Stand. After
drying, the bags were sealed at a heat setting of 3 using the ANKOM Heat Sealer. Samples were
placed on a drying rack and were placed in a Fisher Scientific Isotemp oven at 100 Celsius for
90 minutes. Samples were removed from the oven and immediately placed in an ANKOM
MoistureStop weigh pouch (desiccant pouch) to cool. Bags were removed one at a time from the
desiccant pouch and were weighed on an analytical scale using the Bag Weigh Holder. Bag
weights were recorded on the DFDS. A protein correction was performed using kjeldahl
digestion and distillation, as described above. An ash correction was also performed by burning
the samples as 700 Celsius for 5 hours and recording the weight after ashing. All ashing and
protein values were recorded on the DFDS. Percent IDF, SDF and TDF were then calculated
using the following equations:
•

%IDF or %SDF = (Residue (grams) – protein residue and bag – ash residue and bag –
blank) / original weight of sample x 100%

•

TDF = %IDF + %SDF

SCFA Extraction and Determination
SCFA extractions were performed using a procedure developed by Schwiertz et al. that
was modified.73 One mL of the SCFA extraction solution, containing Oxalic acid (0.1 mol/L),
Sodium Azide (40 mmol/L), and Caproic acid (0.1 mmol/L )(internal standard) was added to 80
mg of a freeze-dried stool sample in a 16 x 100 mm disposable culture tube. The tube was
capped and vortexed for 30 seconds. The tube was placed on a horizontal shaker for 1 hour. The
tube was centrifuged at 4000 rpm for 20 minutes. After centrifuging, the supernatant was
removed and placed in a 1.5mL polypropylene Fisherbrand micro-centrifuge tube. The solution
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was re-centrifuged at 12,000 rpm for 15 minutes. Again, the supernatant was removed and
placed in a new 1.5 mL micro-centrifuge tube. The solution was re-centrifuged at 12,000 rpm for
15 minutes. Finally, the supernatant was removed, placed in a 2 mL amber vial, and was stored
at -80 Celsius until being analyzed using a Shimadzu GC2010 gas chromatograph with SigmaAldrich ZB-Wax Plus capillary column. Samples were run using the SCFA.standard.run.gcm
method adapted from Schaefer et al. shown in Table 6.74
Table 6: SCFA Gas Chromatography Methodology74
SCFA.standard.run.gcm Method
Injection Volume
SPL1 Temperature
Column Parameters:

1 L
750 Celsius
Initial temperature: 50 Celsius
Temperature Hold
Rate
(minutes)
( C)
50
2
15
140
5
10
160
3
10
175
3

FID1 Temperature
End Time

180 Celsius
24 minutes

Statistical Analysis
Descriptive statistics and subsequent analyses were performed using GraphPad Prism.
General linear models were used for all statistical analysis to determine change over time within
the treatment and placebo groups and to determine differences between treatment and placebo
participants. Change over time within a group and differences between groups were considered
significantly significant if a p-value of less than 0.05 was achieved. Standard deviations were
also determined for all dependent variables.
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CHAPTER 4
RESULTS
Participants
Twenty-two participants were enrolled in the study per eligibility criteria. Two
participants were removed from the study, and 20 participants completed the study. One
participant was removed for an injury unrelated to the study that prevented further continuation.
The other was removed for experiencing increased gastrointestinal symptoms while taking the
placebo. Of the 20 that completed the study, group one included 10 participants that took the
treatment (GlutenShield) three times a day for 28 days and group two included 10 participants
that took the placebo three times a day for 28 days.
Demographics
The overall cohort (n=20) had a mean age of 42  17.11, with a mean age of 46.80 
17.25 for the treatment group and a mean age of 37.2  16.42 for the placebo group. The total
cohort was comprised on 30% males (n=6) and 70% females (n=14) with 3 males and 7 females
in both the treatment and placebo groups. The mean BMI for the overall cohort was 28.61 
7.26, with a mean BMI of 24.79  6.42 for the treatment group and a mean BMI of 31.49  7.21
for the placebo group. The treatment group was comprised of 60% normal weight (NW) adults
(n=6), 30% overweight (OW) adults (n=3), and 10% obese (OB) adults (n=1) using BMI
classification. The placebo group was comprised on 20% NW adults (n=2), 30% OW adults
(n=3), and 50% OB adults (n=5). In the overall cohort, 90% (n=18) identified as Caucasian,
while 10% (n=2) identified as other. Demographic results are shown in Table 7.
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Table 7: Demographics
Overall Cohort
N
Gender
Male gender n (%)
Female gender n (%)
BMI
BMI (kg/m2)
-Normal Classification (%)
-Overweight Classification (%)
-Obese Classification (%)
Ethnicity
Caucasian
Other
Age (years)

Placebo
Group
10

p*

20

Treatment
Group
10

6 (30%)
14 (70%)

3 (30%)
7 (70%)

3 (30%)
7 (70%)

1.000
1.000

28.61 ± 7.26
8 (40%)
6 (30%)
6 (30%)

24.79 ± 6.42
6 (60%)
3 (30%)
1 (10%)

31.49 ± 7.21
2 (20%)
3 (30%)
5 (50%)

0.078
0.074
1.000
0.054

18 (90%)
2 (10%)
42.0 ± 17.11

9 (90%)
1 (10%)
46.80 ± 17.25

9 (90%)
1 (10%)
37.2 ± 16.42

1.000
1.000
0.219

Assessments
Food Frequency Questionnaire and Physical Activity
Results from NutritionQuest’s 2014 Block Food and activity questionnaire are shown in
Tables 8 through 12. Meal frequency for the cohort (n=20) averaged 2.63  0.60 and snack
frequency averaged 1.89  0.90 (see Table 8). There were no significant differences in
macronutrient distribution between groups (p>0.05). For the total cohort, daily energy intake
averaged 1543.41  517.95 calories, protein intake averaged 60.26  23.83 grams (15.62% of
total caloric intake), carbohydrate intake averaged 171.72  62.29 grams (44.50% of total caloric
intake), total fat intake averaged 67.65  27.92 grams (39.46% of total caloric intake), fiber
intake averaged 15.22  7.45 grams, insoluble fiber intake averaged 10.86  6.17 grams, and
soluble fiber intake averaged 4.02  1.73 grams. A more detailed breakdown of macronutrient
intakes in shown in Table 9.
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Table 8: FFQ: Meal/Snack Frequency

Item (per day)
Meal frequency
Snack frequency

Meal/Snack Frequency
Treatment Group
Placebo group
(mean  std.)
(mean  std.)
2.6  0.52
2.67  0.71
1.8  0.79

2.00  1.07

Total Cohort
(mean  std.)
2.63  0.60

p*
0.816

1.89  0.90

0.654

Total Cohort
(mean  std.)
1543.41  517.95

p*
0.583

Table 9: FFQ: Macronutrient/ Other Intake

Item (per day)
Energy, total (kcals)

Macronutrient/ Other
Treatment Group
Placebo group
(mean  std.)
(mean  std.)
1609.40  463.41 1447.41  584.75

Protein (g)

64.32  21.67

56.20  26.31

60.26  23.83

0.461

Carbohydrates (g)

178.98 50.44

164.45  74.36

171.72  62.29

0.615

Total fat (g)

69.32  29.97

65.99  27.23

67.65  27.92

0.797

Saturated fat (g)

21.02  8.49

22.08  9.78

21.54  8.93

0.799

Monounsaturated fat
(g)
Polyunsaturated fat
(g)
Cholesterol (mg)

26.07  11.20

24.97  10.22

25.52  10.45

0.822

16.45  9.09

13.34  5.48

14.92  7.48

0.358

211.86  93.93

218.23  101.85

215.08  95.41

0.885

5.73  6.31

4.47  5.06

5.10  5.60

0.630

Total sugar (g)

72.59  35.47

75.93  43.82

74.26  38.84

0.853

Total fiber (g)

16.69  6.97

13.75  7.99

15.22  7.45

0.392

Insoluble fiber (g)

12.04  5.92

9.67  6.49

10.86  6.17

0.403

Soluble fiber (g)

4.55  1.91

3.48  1.43

4.02  1.73

0.175

Alcohol (g)

49

Intake of grains, whole grains, vegetables, fruit, dairy, protein, and beneficial oil intake is
also shown in Table 10. Results are reported in equivalents shown in relation to the United States
Department of Agriculture’s Dietary Guidelines for Americans/ MyPlate recommendations.
Grain intake averaged 4.04  2.34 oz per day, whole grain intake averaged 0.92  0.58 oz per
day, vegetable intake averaged 1.06  0.63 cups per day, fruit intake averaged 0.73  0.75 cups
per day, dairy intake averaged 1.26  0.65 cups per day, protein intake averaged 5.2  3.88 oz
per day, and beneficial oil intake averaged 5.11  2.67 teaspoons per day. All p-values for
measurement between groups for MyPlate equivalents were greater than 0.05. When comparing
intakes of food groups to the MyPlate recommendations, the total cohort averaged a lower intake
of grains (average intake (AI) : 4.04  2.34, recommended intake (RI): 5 oz equivalent), whole
grains (AI: 0.92  0.58, RI: 3 oz-equivalent), fruit (AI: 0.73  0.75, RI: 1.5 cup equivalent),
dairy (AI: 1.26  0.65, RI: 2.5 cup equivalent), and beneficial oils (AI: 5.11  2.67, RI: 17
grams) based on a 1,400 calorie meal pattern.75
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Table 10: FFQ: MyPlate Equivalents

Item (per day)

Grain (oz)

MyPlate Equivalents
Treatment
Placebo group
Group (mean 
(mean  std.)
std.)
4.34  1.63
3.74  3.0

Total Cohort
(mean  std.)

P*

4.04  2.34

0.512

Whole grain (oz)

1.16  0.65

0.67  0.40

0.92  0.58

0.060*

Vegetable, total (no
legume or potato) (cup)
Vegetable, potato and
legume (cup)
Fruit, total (including
juice) (cup)
Dairy, total (cup)

1.30  0.71

0.83  0.47

1.06  0.63

0.100

0.29  0.22

0.20  0.12

0.25  0.18

0.265

0.53  0.38

0.93  0.98

0.73  0.75

0.247

1.23  0.60

1.29  0.73

1.26  0.65

0.847

Protein foods: meat,
poultry, seafood (oz)
Protein foods: nuts and
seeds (oz)
Protein foods: eggs (oz)

3.23  1.68

3.12  1.89

3.17  1.74

0.894

1.34  1.60

0.66  0.52

1.00  1.21

0.217

0.40  0.23

0.42  0.32

0.41  0.27

0.875

Protein foods: legumes and
soy (oz)
Beneficial oils (tsp)

0.92  0.85

0.33  0.12

0.62  0.66

0.042*

5.63  3.27

4.59  1.94

5.11  2.67

0.398

Micronutrient distribution of daily vitamin and mineral intake is shown in Table 11. No
significant differences were indicated between groups for micronutrient intake (p>0.05). Physical
activity results are shown in Table 12. Overall daily estimated energy expenditure for all
activities averaged 730.09  565.16 calories and estimated activity expenditure excluding work
and chores averaged 206.65  245.84 calories per day. Minutes spent performing activities per
day averaged 89.79  66.42 for light activity, 46.51  67.86 for moderate activity, and 18.44 
23.59 for vigorous activity.
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Table 11: FFQ: Micronutrient Intake

Item (per day)
Vitamin A (mg)

Micronutrient Intake
Treatment Group
Placebo group
(mean  std.)
(mean  std.)
631.70  251.54
494.81  158.12

Total Cohort
(mean  std.)
563.25  216.20

P*
0.162

Vitamin E (mg)

8.25  3.53

6.19  1.82

7.22  2.93

0.118

Vitamin E, added
(mg)
Vitamin D (mcg)

0.56  0.90

0.26  0.20

0.41  0.65

0.311

4.06  1.97

2.93  1.22

3.49  1.70

0.141

Vitamin K (mcg)

128.82  75.79

82.30  36.54

105.56  62.63

0.097

Vitamin C (mg)

53.12  25.33

56.22  30.04

54.67  27.09

0.806

Thiamin (mg)

1.90  1.07

1.58  0.76

1.74  0.92

0.451

Riboflavin (mg)

1.27  0.39

1.04  0.50

1.15  0.45

0.265

Niacin (mg)

21.41  9.22

19.01  9.43

20.21  9.16

0.573

Vitamin B6 (mg)

1.93  1.34

1.74  0.81

1.84  1.08

0.713

340.02  103.41

250.52  95.79

295.27  107.33

0.060*

B12 (mcg)

4.61  2.83

4.05  2.41

4.33  2.58

0.642

B12, added (mcg)

1.25  2.43

1.03  2.41

1.14  2.58

0.790

Choline (mg)

261.62  89.50

220.77  80.70

241.19  85.55

0.298

Calcium (mg)

734.12  212.29

717.08  319.12

725.60  263.94

0.890

12.014  4.18

9.19  3.58

10.60  4.05

0.122

Magnesium (mg)

277.62  107.21

208.27  66.95

242.94  93.99

0.100

Phosphorus (mg)

1102.78  335.95

984.69  421.37

1043.73  375.81

0.497

Potassium (mg)

2323.44  758.70

1814.77  703.89

2069  758.58

0.536

Sodium (mg)

2830.11  871.24

2529.48  1228.33

2679.80  1047.87

0.536

Folate (mcg)

Iron (mg)
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Zinc (mg)

9.92  3.13

8.13  3.68

9.02  3.45

0.257

Copper (mg)

1.25  0.55

0.95  0.27

1.10  0.45

0.141

Selenium (mg)

85.19  27.66

73.08  36.40

79.14  32.07

0.413

Caffeine (mg)

189.19  111.93

120.59  109.75

155.16  113.57

0.180

Table 12: FFQ: Physical Activity

Category (per day)

Estimated energy
expenditure, all activities
(kcals)
Estimated energy
expenditure, excluding
work and chores (kcals)
Estimated light activity
(minutes)
Estimated moderate
activity (minutes)
Estimated vigorous activity
(minutes)
Estimated recreation
(minutes)

Physical Activity
Treatment
Placebo group
Group (mean 
(mean  std.)
std.)
497.85  331.73 939.10  662.21

Total Cohort
(mean  std.)

P*

730.09  565.16

0.089

153.62  155.49

254.38  306.67

206.65  245.84

0.388

78.36  60.50

101.23  73.23

89.79  66.42

0.456

36.09  31.62

56.93  92.08

46.51  67.86

0.507

11.29  15.25

25.60  28.79

18.44  23.59

0.182

23.17  19.51

24.61  29.01

23.89  24.07

0.898

Gastrointestinal Symptoms
Participants completed a gastrointestinal symptoms (GIS) questionnaire using a 7-point
Likert scale. Symptoms measured included heartburn, acid regurgitation, bloating, nausea,
abdominal distension, eructation, increased gas, decreased passage of stools, increased passage
of stools, loose stools, hard stools, urgent need for defecation, and feeling of incomplete
evacuation. Out of a possible 91 points, the participants averaged a GIS score of 28.9  9.65. The
treatment group had a pre mean GIS score of 29.4  9.18 and a post mean GIS score of 22.9 
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6.42 (p=0.083091). The placebo group had a pre mean GIS score of 28.4  10.57 and a mean
post GIS score of 21.2  6.29 (p=0.080676). A mean reduction of 6.5 points was observed in the
treatment group, while a mean reduction of 7.2 points was observed in the placebo group. A
significant reduction in bloating (3.6  1.65 vs. 2.3  0.82, p=0.038475) was observed in the
treatment group. An approaching significant reduction was observed for loose stools in the
treatment group (2.5  1.18 vs. 1.6  0.84, p=0.065169). An approaching significant reduction
was also observed in the placebo group for bloating (3.1  1.66 vs. 1.9  0.99, p=0.065897) and
increased gas (2.1  1.45 vs. 1.8  1.30, p=0.066324). Starting values from both groups were
compared and no significant differences were observed for heartburn (p=0.47), acid regurgitation
(p=0.18), bloating (p=0.51), nausea (p=0.38), abdominal distension (p=0.62), eructation
(p=0.31), increased gas (p=0.89), decreased passage of stools (p=0.89), increased passage of
stools (p=0.52), loose stools (p=0.60), hard stools (p=0.70), urgent need for defecation (p=0.79),
feeling of incomplete evacuation (p=0.64), or total GIS (p=0.82). Change from pre to post and
significance for the treatment and placebo groups are shown in Table 13.
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Table 13: Gastrointestinal Symptoms
Gastrointestinal Symptoms
Symptom

Treatment
Pre
(mean 
stdev.)
Heartburn 1.6  0.97

Treatment
Post
(mean 
stdev.)
1.1  0.32

Treatment p*

Placebo
Post
(mean 
stdev.)
1.8  0.79

Placebo
p*

0.137

Placebo
Pre
(mean 
stdev.)
2.0  1.41

0.701

Delta
between
groups
p*
0.569

Acid
Regurgitation
Bloating

1.1  0.32

1.2  0.63

0.660

1.5  0.85

1.6  1.07

0.820

1.000

3.6  1.65

2.3  0.82

0.038*

3.1  1.66

1.9  0.99

0.066*

0.894

Nausea

1.4  0.96

1.2  0.42

0.556

1.8  1.03

1.1  0.32

0.055*

0.216

Abdominal
Distension
Eructation

2.9  1.45

1.9  1.29

0.120

2.5  2.01

1.4  0.52

0.112

0.889

2.9  1.91

2.0  1.33

0.238

2.1  1.45

1.8  1.03

0.600

0.472

Increased Gas

3.0  1.76

2.2  1.03

0.232

2.9  1.29

1.8  1.30

0.066*

0.675

Decreased
Passage of
Stools
Increased
Passage of
Stools
Loose Stools

2.0  1.15

1.9  1.85

0.886

1.9  2.02

1.9  1.60

1.000

0.911

1.9  1.10

2.1  1.45

0.732

1.5  1.58

1.5  0.85

1.00

0.812

2.5  1.18

1.6  0.84

0.065*

2.9  2.02

1.8  1.32

0.167

0.748

Hard Stools

2.0  1.25

1.8  1.23

0.722

1.8  1.03

1.6  0.70

0.618

1.000

Urgent Need
for Defecation
Feeling of
Incomplete
Evacuation

2.1  1.60

1.5  0.53

0.274

2.3  1.64

2.1  1.45

0.343

1.000

2.4  1.35

2.1  1.52

0.647

1.7  1.06

1.3  0.48

0.115

0.247
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*Each color in the graph represents an individual participant in the study

Figure 2: Change in Mean GI Symptoms in Treatment and Placebo Groups
The change in treatment group compared to the change in placebo group was
insignificant for heartburn (p=0.569275418), acid regurgitation (p=1.00), bloating
(p=0.894446423), nausea and vomiting (p= 0.216268549), abdominal distension
(p=0.888985282), eructation (0.426753529), increased gas (p=0.674699956), decreased gas
(p=0.911541284), increased passage of stools (p=0.811708962), loose stools (p=0.747918259),
hard stools (p=1.00), urgent need for defecation (p=1.00), feeling of incomplete evacuation
(p=0.246784597), and total GI symptoms (p0.836516559).
POMS Assessment
The Profile of Mood States self-assessment measured initial and change in mood states
for anger/ hostility, confusion/ bewilderment, depression/ dejection, fatigue/ intertia, tension/
anxiety, vigor/ activity, and friendliness. Measurements are reported as a t-score calculated by
MHS Assessments. The starting mean t-score for both the treatment and placebo groups within
each category fell within the typical score range (t-score of 40-59). Additionally, there was no
significant change over time in either group, nor was there a significant difference between
groups. Change from pre to post and significance for the treatment and placebo groups are shown
in Table 14.
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Table 14: POMS T-Scores
POMS (T-Score)

Total Mood
Disturbance
AngerHostility
ConfusionBewilderment
DepressionDejection
FatigueInertia
TensionAnxiety
Vigor-Activity
Friendliness

Treatment
Pre
(mean 
stdev.)
44.5  5.44

Treatment
Post
(mean 
stdev.)
45.3  9.87

Treatment p*

40.3  2.63

42.5  7.17

0.374

43.2  3.77

43.4  6.15

0.931

43.0  2.0

44.8  7.89

0.493

44.4  9.23

44.8 10.25

0.928

41.5  5.40

42.0  7.20

0.862

47.0  7.63

48.8 10.80

0.664

53.1  3.48

54.7  9.24

0.614

0.825

Placebo
Pre
(mean 
stdev.)
44.1 
4.23
42.1 
5.55
42.0 
3.94
43.8 
3.05
38.8 
5.14
41.9 
4.82
44.2 
8.35
48.0 
8.06

Placebo
Post
(mean 
stdev.)
42.2 
5.51
40.0 
1.76
41.5 
3.81
44.0 
2.0
38.3 
5.29
41.9 
4.53
49.4 
8.67
47.6 
10.95

Placebo
p*

0.399

Delta
between
groups
p*
0.373

0.269

0.165

0.776

0.765

0.864

0.508

0.833

0.712

1.000

0.864

0.189

0.283

0.927

0.549

Blood Analysis
Immunoglobins
The concentration of immunoglobins (ug/mL) IgG1, IgG2, IgG3, IgG4, IgA, and IgM
was measured via ELISA analysis of the pre and post blood samples of each participant in
duplicate. An approaching significant reduction was observed for IgG1 in the treatment group
(7344.04  2381.53 vs. 5094.64 vs  2729.10, p=0.0651850) with no significant change from pre
to post measured in the placebo group (8986.89  2753.77 vs. 7901.47  2919.83, p=0.429088).
A significant reduction was observed in the treatment group for IgG2 from pre to post (7110.44
 2437.07 vs. 4185.56  1901.13, p=0.007813) with no significant change observed in the
placebo group from pre to post (7748.76  3024.44 vs. 5710  1975.02, p=0.109788). No
changes were seen from pre to post in either the treatment or placebo groups for IgG3, IgG4,
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IgA, or IgM. No significant changes were observed when comparing the change in the treatment
group to the change in the placebo group for all immunoglobins (p>0.05). Change from pre to
post and significance for the treatment and placebo groups are shown in Table 15.
Table 15: Immunoglobins
Immunoglobins (ug/mL)
Treatment
Pre
(mean 
stdev.)
7344.04 
2381.53
7110.44 
2437.07
693.4 
518.92
342.4 
271.51
2046.24 
711.41
2247.4 
1458.65

IgG1
IgG2
IgG3
IgG4
IgA
IgM

Treatment
Post
(mean 
stdev.)
5094.64 
2729.10
4185.56 
1901.13
505.76 
451.30
257.6 
241.49
1662.92 
835.30
1683.84 
1614.82

Treatment p*

0.065*
0.008*
0.400
0.470
0.284
0.424

Placebo
Pre
(mean 
stdev.)
8986.89 
2753.77
7748.76 
3024.44
664.4 
362.62
585.38 
532.20
2316.09 
1058.41
2136.4 
1373.22

Placebo
Post
(mean 
stdev.)
7901.47 
2919.83
5710 
1975.02
589.29 
336.46
564.89 
533.61
2197.42 
987.08
1855.02 
976.04

Placebo
p*

0.429

Delta
between
groups
p*
0.304

0.110

0.462

0.655

0.443

0.936

0.276

0.809

0.301

0.623

0.523

Cytokines
The concentration of cytokines (pg/mL) IL-2, IL-6, IL-8, and TNF-a was measured via
ELISA analysis of the pre and post blood samples of each participant in duplicate. No significant
changes were seen from pre to post in the treatment group for all measures. A significant
decrease was measured from pre to post in the placebo group for TNF-a (35.30  8.32 vs. 26.01
 7.70, p=0.018498). No significant differences were observed when comparing the change in
the treatment group to the change in the placebo group (p>0.05). Change from pre to post and
significance for the treatment and placebo groups are shown in Table 16.
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Table 16: Cytokines
Cytokines (pg/mL)
Treatment
Post
(mean 
stdev.)
2.36  0.64

Treatment p*

IL-2

Treatment
Pre
(mean 
stdev.)
3.07  1.43

Placebo
Post
(mean 
stdev.)
2.46  0.67

Placebo
p*

0.172

Placebo
Pre
(mean 
stdev.)
2.32  0.82

0.663

Delta
between
groups
p*
0.144

IL-6

2.23  0.30

2.21  0.40

0.921

2.21  0.29

2.14  0.37

0.659

0.768

IL-8

10.32  2.78

9.27  2.03

0.344

9.35  1.79

9.35  1.10

0.998

0.288

TNF-a

49.8  39.77

31.7013.72

0.190

35.30 8.32

26.017.70

0.018*

0.397

Fecal Analysis
Freeze Drying
No significant change was observed in the dry weight (grams) of the stool sample from
pre to post in the treatment (13.19  10.37 vs. 11.45  9.81, p=0.704937) or placebo groups
(21.12  15.57 vs. 20.98  15.06, p=0.563617). The treatment group began with a mean percent
dry weight of 25.94  5.52 and ended with a mean percent dry weight of 26.87  5.64
(p=0.713393). The placebo group began with a mean percent dry weight of 27.75  5.80 and
ended with a mean percent dry weight of 26.04  7.16 (p=0.563617). The delta (change in) dry
weight mass was not significant between groups (p=0.756729), nor was the delta % dry weight
(p=0.385334). Change from pre to post and significance for the treatment and placebo groups are
shown in Table 17.
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Table 17: Freeze-Drying Dry Weights
Dry Weight

Dry
Weight
(g)
Dry
Weight
(%)

Treatment
Pre
(mean 
stdev.)
13.1910.37

Treatment
Post
(mean 
stdev.)
11.45  9.81

Treatment p*

25.94  5.52

26.87  5.64

0.713

0.705

Placebo
Pre
(mean 
stdev.)
21.12 
15.57

Placebo
Post
(mean 
stdev.)
20.9815.06

Placebo
p*

0.984

Delta
between
groups
p*
0.757

27.75 
5.80

26.04  7.16

0.564

0.385

Protein
No significant change was observed in the total percentage of protein of the stool sample
from pre to post in the treatment (28.32  6.73 vs. 33.39  10.10, p=0.236885) or placebo groups
(30.45  5.49 vs. 30.14  8.02, p=0.925755). The change in protein percentage in the treatment
group compared to the change in the protein percentage in the placebo group was also nonsignificant (p=0.28021). Change from pre to post and significance for the treatment and placebo
groups are shown in Table 18.
Table 18: Percent Protein
Protein (%)
Treatment
Pre
(mean 
stdev.)
28.32  6.73

Treatment
Post
(mean 
stdev.)
33.39  10.10

Treatment p*

Placebo Pre
(mean 
stdev.)

Placebo Post
(mean 
stdev.)

Placebo
p*

Delta
between
groups p*

0.237

30.45  5.49

30.14  8.02

0.926

0.280
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Fiber
Percentage of insoluble, soluble, and total dietary fiber was measured from freeze-dried
stool samples using an ANKOM Dietary Fiber Analyzer in duplicate. In the treatment group, no
significant change was measured for percentage of insoluble dietary fiber (41.54  10.72 vs
39.92  7.12, p=0.686656), soluble dietary fiber (10.33  4.86 vs. 12.24  6.59, p=0.50162), or
total dietary fiber (51.88  10.39 vs. 53.04  7.79, p=0.779015). In the placebo group, there was
no significant change in the percentage of soluble dietary fiber (15.49  16.46 vs. 10.51  3.81,
p=0.389839) or total dietary fiber (50.37  15.61 vs. 54.43  8.23, p=0.499139); however, there
was a significant increase in the percentage of insoluble dietary fiber (34.42  10.67 vs. 43.79 
5.48, p=0.032455) in the placebo group. The change in percentage of dietary fiber between
groups was significant for insoluble dietary fiber (p=0.011882187), but was insignificant for
soluble dietary fiber (p=0.306893128) and total dietary fiber (p=0.68386199). Change from pre
to post and significance for the treatment and placebo groups are shown in Table 19.
Table 19: Percent Dietary Fiber
Dietary Fiber (%)
Treatment
Post
(mean 
stdev.)
39.92 
7.12

Treatment p*

Placebo Pre
(mean 
stdev.)

Placebo Post
(mean 
stdev.)

Placebo
p*

Insoluble
(%)

Treatment Pre
(mean 
stdev.)
41.54
10.72

0.687

34.42 
10.67

43.79  5.48

0.032*

Delta
between
groups
p*
0.012*

Soluble
(%)

10.33
4.86

12.24 
6.59

0.502

15.49 
16.46

10.51  3.81

0.390

0.307

Total (%)

51.88
10.39

53.04 
7.79

0.779

50.37 
15.61

54.43  8.23

0.499

0.684
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SCFA
Both concentration (mmol/L) and area percent under the curve were measured for SCFA
composition of the freeze-dried stool samples in duplicate. No significant change in area percent
under the curve or concentration was measured from pre to post in the treatment group. No
significant change in area percent under the curve was seen for the placebo group from pre to
post; however, a significant change was observed in the placebo group for concentration of
Isobutyrate (0.51  0.13 vs. 0.40  0.14, p=0.078227) and Isovalerate (0.65  0.16 vs. 0.50 
0.16, p=0.049512). The change in the treatment group compared to the change in the placebo
group approached significance for butyrate concentration (p=0.054600918). Change from pre to
post and significance for the treatment and placebo groups are shown in Table 20 and 21.
Table 20: SCFA: Area Percent Under the Curve

SCFA

Treatment
Pre (mean
 std.)

Area Percent Under the Curve
Treatment
TreatPlacebo
Post (mean
ment
Pre (mean
p*
 stdev.)
 stdev.)

Acetate

34.668.33

32.80  7.65

0.610

Propionate

21.504.07

20.89  3.88

0.734

Isobutyrate

4.161.77

4.10  1.79

0.941

Butyrate

25.375.88

28.14  5.06

0.274

Isovalerate

7.78  3.95

7.52  3.76

Valerate

5.09  2.55

Isocaproate

Placebo
Post
(mean 
stdev.)
33.26 5.03

Placebo
p*

0.716

Delta
between
groups
p*
0.283

24.96  3.62

0.883

0.525

3.92  1.27

0.708

0.744

24.41  4.15

0.792

0.174

0.882

25.18 
8.11
7.57  3.19

7.06  2.70

0.704

0.811

4.92  2.18

0.875

5.33  1.13

5.20  1.23

0.788

0.945

0.19  0.13

0.26  0.23

0.351

0.22  0.19

0.30  0.32

0.462

0.954

Caproate

1.09  1.13

1.18  0.95

0.852

0.42  0.60

0.86  0.82

0.194

0.327

Heptanoate

0.17  0.26

0.06  0.10

0.236

0.02  0.07

0.02  0.07

0.997

0.234

C2+C3+C4

81.538.29

81.83 8.43

0.937

82.29 
5.51

82.64  5.19

0.886

0.979
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32.42
5.17
24.68 
4.62
4.15  1.44

Table 21: Dietary Fiber: Concentration
Concentration (mmol/L)
SCFA

Treatment
Pre
(mean 
stdev.)

Treatment
Post
(mean 
stdev.)

Treatment
p*

Placebo
Pre
(mean 
stdev.)

Placebo
Post
(mean 
stdev.)

Placebo
p*

Delta
between
groups
p*

Acetate

13.52 7.20

13.89  7.15

0.907

13.04  7.07

0.273

0.159

Propionate

4.39  2.30

4.51  2.29

0.913

4.85  2.37

10.09
4.27
3.69  1.31

0.192

0.170

Isobutyrate

0.53  0.30

0.57  0.30

0.808

0.51  0.13

0.40  0.14

0.078*

0.124

Butyrate

3.89 2.29

4.60  2.70

0.533

3.62  2.28

2.70  1.31

0.282

0.055*

Isovalerate

0.70  0.46

0.74  0.44

0.838

0.65  0.16

0.50  0.16

0.0495*

0.135

Valerate

0.68  0.45

0.69  0.38

0.960

0.67  0.19

0.55  0.17

0.158

0.221

Isocaproate

0.36  0.01

0.42  0.16

0.298

0.33  0.12

0.31  0.12

0.750

0.173

Caproate

0.61  0.21

0.61  0.14

0.958

0.50  0.20

0.52  0.20

0.800

0.856

Heptanoate

0.68  0.62

0.35  0.48

0.188

0.12  0.39

0.12  0.39

0.997

0.259

C2+C3+C4

21.8010.78 21.0710.83

0.882

21.5111.06 16.476.59

0.232

0.252

Total
SCFA

25.3711.33 26.3811.89

0.848

24.2911.06 16.476.59

0.224

0.133

63

CHAPTER 5
DISCUSSION
Participants
The total sample size for this study was 20, 10 of which were randomized to receive the
treatment and 10 of which who were randomized to complete the placebo. A relatively small
sample size with a large number of participant variables, such as differences in age, weight
classification, lifestyle, and dietary habits could account for small changes in primary outcome
measures over time.
Demographics
There were no significant differences for age, gender, or ethnicity between the treatment
and placebo groups. That being said, the was a wide standard deviation in the age of the
participants in both groups (treatment: 46.80  17.25, placebo: 37.2  16.42). The total cohort
had a mean age of 42  17.11. Typically, the prevalence of GI symptoms is higher in adults over
age 50. That being said, several of the participants were recruited from East Tennessee State
University which may have contributed to a younger participant cohort. Additionally, the
majority of participants from each group (70%) were female. This supports research that shows
that the prevalence of constipation and diarrhea is higher in women compared to men.
Approaching significant differences were seen when looking at the BMI weight classification of
the treatment and placebo groups. The treatment group had more normal weight (n=6), an equal
number of overweight (n=3), and a lower number of obese (n=1) participants compared to the
placebo group (normal weight: n=2, overweight: n=3, and obese: n=5). Since weight
classification may influence gut fermentation and the gut microbiome, differences in weight
between groups may affect the results of the study.
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Assessments
Food Frequency Questionnaire and Physical Activity
Mean daily caloric intake for the total cohort averaged 1543  517.95 calories which is
typical for most Americans, particularly because the cohort was comprised of 70% females
(n=14) which typically have lower energy requirements compared to males. Interestingly the
total cohort had a higher percentage of calories from fat (39.46%) compared to the Dietary
Guidelines for Americans recommendation of 20-35% of total calories per day.75 Calories from
saturated fat averaged 193.86 (12.56%) which is slightly higher than the recommended intake of
saturated fat (<10%).75 Additionally, fiber intake for total cohort averaged 15.22  7.45 grams
per day which is below the recommended intake of 20-35 grams per day (varies depending on
age and sex).75 Dietary intakes higher in total and saturated fat and lower in fiber compared to
the recommended intake can be a contributing factor to gastrointestinal symptoms in this
population.
Of importance, there was not a significant difference in dietary intake or composition
between groups at the start of the study. Since diet composition influences gut fermentation and
the gut microbiome, differences between groups could have skewed the interpretation of results.
Gastrointestinal Symptoms
Out of a possible 91 points, participants in both groups averaged a GIS score of 28.9 
9.65. This indicates that participants had relatively mild gastrointestinal symptoms, but each
participant met the inclusion criteria of the study in that each person self-reported the presence of
at least one GIS three or more times per week. Additionally, there was no significant difference
in starting values between groups which allowed for accurate analysis of ending measures of
gastrointestinal upset.
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A decrease in the presence of total GI symptoms was observed in the treatment group
from start to finish and a significant decrease was observed for bloating and incidence of loose
stools in the treatment group. These findings support that combination probiotic, prebiotic, and
enzyme can improve certain self-reported measures of GIS incidence.
POMS Assessment
Research shows that individuals with GI upset have an impaired quality of life compared
to individuals without GI upset. The mean results of the POMs questionnaire for this study;
however, suggests that the starting mood state of all participants (n=20) falls within the normal
or typical response range. Additionally, a significant change was not observed for any mood state
over time in the treatment or placebo group. Future research may consider utilizing the POMs
questionnaire as a method of inclusion. For example, ‘potential research subjects must exhibit an
elevated or very elevated t-score for total mood disturbance to be included’. This would be a
better method to evaluate change in mood state as a result of synbiotic supplementation.
Ultimately, results of this study suggest that individuals with GI upset do not have an altered
mood state; however, the sample size was very small and a larger research study should be
conducted to confirm this.
Blood Analysis
Immunoglobins
A significant reduction in serum IgG levels from start to finish in the treatment group
could be a serum response to a change in the gut microbiome; however, research is inclusive on
whether or not the gut microbiota can provoke systemic change to IgG levels. 76
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Cytokines
One potential effect of probiotic intake is a reduction in serum inflammatory markers.
The results of this study do not indicate that GlutenShield has an effect on IL-2, IL-6, IL-8, or
TNF-a concentrations. An anomaly was observed in the placebo group, which experienced a
significant reduction in TNF-a from start to finish.
Fecal Analysis
Fiber
There are two primary classifications for fiber: insoluble and soluble. Soluble fiber delays
gastric emptying and increases transit time (slows movement through GI tract). Insoluble fiber
decreases transit time (speeds up movement through GI tract) and increase fecal bulk. Typically,
soluble fiber assists with diarrhea while insoluble fiber assists with constipation. Because a
common claim associated with consuming probiotics is better bowel regularity, we predicted a
change in fecal dietary fiber concentrations as a result of GlutenShield supplementation. That
being said, no significant change was observed over time. Fecal dietary fiber concentrations are
strongly influenced by one’s diet starting and ending values alone are not a good indicator of
typical fecal fiber concentrations of those with gastrointestinal upset. The change over time,
however, would be a good measurement of effect.
SCFA
One of the primary hypotheses of this research is that synbiotic (prebiotic and probiotic)
supplementation would increase fecal SCFA concentrations as an indication of change in total
gut fermentation. No significant change was seen in the treatment group for any SCFA over time
and there was no significant change between groups for SCFAs. These results indicate that there
was no change in fermentation from start to finish. While probiotics may have an indirect effect
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on SCFA concentration, prebiotics, in particular, have been shown to have the greatest potential
to increase SCFA production and as a result, affect the microbial composition of the gut.
Different prebiotic fibers have different effects on SCFA production. That being said, the
GlutenShield supplement contained several different types of prebiotics (Chitosan
oligosaccharide, fructooligosaccharides, alfalfa, Emblica officinalis extract, papaya juice
powder, fulvic acid, and ionic minerals). The GlutenShield supplement may need increased
amounts of prebiotics or a longer period of supplementation for changes to SCFA concentrations
to be observed.
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CHAPTER 6
CONCLUSION
Research findings suggest that GlutenShield was well tolerated and perceived to be
beneficial compared to the placebo. Analysis of the dietary recall shows that the participants had
higher consumption of total fat and saturated fat while they had lower consumption of dietary
fiber compared to the recommendations for Americans. Additionally, intake of grains, whole
grains, fruit, dairy, and beneficial oils fell below the recommended intake. These dietary patterns
may be a contributing cause of gastrointestinal upset in the population. Results suggest that
individuals with minor GI upset do not have altered mood states. Additionally, the mood state is
not affected by GS supplementation. Blood analysis showed unremarkable changes to
inflammatory markers; however, a significant reduction in IgG levels was observed in the
treatment group. This reduction could be in response to a change in the gut microbiome;
however, no definitive statements can be made about this change. Last, no changes to gut
fermentation (SCFAs) were observed following GS supplementation.
There were several limitations to this study. First, the sample size of the study was fairly
small (n=20). While this is large enough to achieve statistical significance, a larger study may be
needed to observe true effects of GS supplementation. Second, while it takes a minimum of two
weeks to observe changes to fermentation and the gut microbiome, increasing the length of study
to greater than a month may result in a larger improvement in measurements of change. Third,
demographically, there was a wide range of variability in age, gender, and weight classification
which can all impact the results of the study. And fourth, while we had planned to include
microbiome analysis in this study, time constraints of thesis completion resulted in an inability to

69

complete the analysis. Microbiome analysis is currently being completed; however, data is not
available to make a definitive conclusion on the effects of GlutenShield on the gut microbiome.
Further research is undeniably needed in the area of prebiotic, probiotic, and enzyme
supplementation with consideration to the effect on the human gut microbiome, particularly in
those with gastrointestinal upset. Chronic gastrointestinal upset effects ~33.8% of the population
and results in significant number of healthcare visits and hospitalizations annually and synbiotics
may be a novel therapy for GI upset. Additionally, supplemental use of probiotics, prebiotics,
and enzymes is growing and practitioners must have evidenced-based research to support their
use in a clinical setting. Larger studies with less demographic variables along with future
analysis of microbiome data could provide additional insight into the effects of probiotic,
prebiotic, and enzyme supplementation in individuals with gastrointestinal upset. Additionally,
studies targeting specific gastrointestinal symptoms (only constipation or only diarrhea) or
gastrointestinal conditions (i.e. gluten sensitivity) may result in more conclusive data.
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